Correction: Molecular resistance mechanisms to newly approved antibiotics (2017–2025) in WHO priority pathogens
Year: 2026
Type: erratum
Abstract: A Correction on: Sartori M, Toppo S and Lavezzo E (2026) Molecular resistance mechanisms to newly approved antibiotics (2017)(2018)(2019)(2020)(2021)(2022)(2023)(2024)(2025) in WHO priority pathogens. Front. Microbiol. 16:1719798. doi: 10.3389/fmicb.2025.1719798 The hierarchical structure of sections and sub-sections were incorrectly formatted in the final version of the article.• The bullet points starting at "In E. coli, expression of the AmpC…" are intended as sub-sections of "Enzymatic inactivation", page 4, Aztreonam-avibactam.• The sections starting at "Alterations in iron transport systems." are intended as sub-sections of "Resistance mechanisms", page 5, Cefiderocol.• The sections starting at "A. baumannii:" are sub-subsections of the section "Alterations in iron transport systems", page 6, Cefiderocol.• Similarly, the sections starting at "Reduced outer membrane permeability." are sub-sections of "Resistance mechanisms", page 7, Meropenem-vaborbactam.• The sections at "OmpK35 inactivation:" are sub-sections of the "K. pneumoniae" , page 7, Meropenem-vaborbactam.• Sections beginning at lines "Mutations in ddn" are sub-sections of "Resistance mechanisms", page 8, Pretomanid.• Sections beginning at "Increased efflux pump expression" are sub-sections of "Resistance mechanisms", page 8, Lefamulin.• Sections beginning at lines "Efflux pump overexpression" are sub-sections of "Resistance mechanisms", page 9, Omadacycline.Last Name author1 et al.Frontiers Media SA PAGE \* Arabic \* MERGEFORMAT 3• Sections beginning at lines "Efflux pump overexpression" are sub-sections of "Resistance mechanisms", page 9, Eravacycline.• Sections beginning at "Modification of target sites" are sub-sections of "Resistance mechanisms", page 10, Plazomicin.• Sections beginning at "Enzymatic inactivation" are sub-sections of "Resistance mechanisms", page 11, Rifamycin SV.• Sections beginning at "Target site modifications" are sub-sections of "General resistance mechanisms", page 12, Quinolones and fluoroquinolones.• Sections beginning at "Increased efflux pump expression" are sub-sections of "Resistance mechanisms", page 12, Delafloxacin.The original version of this article has been updated.
Source: Frontiers in Microbiology
Author: Frontiers Production Office
Institution: Frontiers Media SA (Switzerland)
Language: English
Subfield: Molecular Medicine
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7128788560
Cites:
Cited by:
Related to: